Lava Therapeutics Announces Treatment of First Patient in Phase I/IIa Clinical Trial of LAVA-051 for Multiple Hematological Malignancies

LAVA Therapeutics N.V. announced dosing of the first patient in the company’s Phase I/IIa clinical trial of LAVA-051 in patients with relapsed and/or refractory chronic lymphocytic leukemia, multiple myeloma and acute myeloid leukemia.